newsfilter
← Latest News
Business Wire·

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated ARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026 Cash runway extended into Q2 2028 Investor